Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway

Nature Communications

Volumn 3, Issue , 2012, Pages

  Arabi, Azadeh ^a   Ullah, Karim ^a   Branca, Rui M M ^a,b   Johansson, Johan ^c   Bandarra, Daniel ^d   Haneklaus, Moritz ^a   Fu, Jing ^e   Ariës, Ingrid ^f   Nilsson, Peter ^g   Den Boer, Monique L ^f   Pokrovskaja, Katja ^a   Grandér, Dan ^a   Xiao, Gutian ^e   Rocha, Sonia ^d   Lehtiö, Janne ^a,b   Sangfelt, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SCIENCE FOR LIFE LABORATORY   (Sweden)

^c Swedish Defence   (Sweden)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; PROTEIN P52; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE FBW7; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; UBIQUITINATION; BIOLOGY; CELL LINE; GENETICS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; NF-KAPPA B P52 SUBUNIT; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; UBIQUITIN-PROTEIN LIGASES;

EID: 84864837496     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms1975     Document Type: Article

References (47)

1. Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. 8, 83-93 (2008). (Pubitemid 351161321)
2. Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316-322 (2001). (Pubitemid 32905853)
3. Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl Acad. Sci. USA 101, 9085-9090 (2004). (Pubitemid 38781615)
4. Oberg, C. et al. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. The Journal of biological chemistry 276, 35847-35853 (2001).
5. Inuzuka, H. et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471, 104-109 (2011).
6. Tetzlaff, M. T. et al. Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl Acad. Sci. USA 101, 3338-3345 (2004). (Pubitemid 38338196)
7. Rajagopalan, H. et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 428, 77-81 (2004). (Pubitemid 38332360)
8. Akhoondi, S. et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67, 9006-9012 (2007). (Pubitemid 47535882)
9. Tan, Y., Sangfelt, O. & Spruck, C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett. 271, 1-12 (2008).
10. Hao, B., Oehlmann, S., Sowa, M. E., Harper, J. W. & Pavletich, N. P. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131-143 (2007). (Pubitemid 46550934)
11. Nash, P. et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414, 514-521 (2001). (Pubitemid 33131529)
12. Welcker, M. & Clurman, B. E. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div. 2, 7 (2007).
13. Orlicky, S., Tang, X., Willems, A., Tyers, M. & Sicheri, F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 112, 243-256 (2003). (Pubitemid 36144113)
14. Baldwin, A. S. Jr. The NF-kappaB and I kappaB proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649-683 (1996). (Pubitemid 26130197)
15. Barre, B. & Perkins, N. D. A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J. 26, 4841-4855 (2007). (Pubitemid 350191299)
16. Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71-85 (2011).
17. Shih, V. F., Tsui, R., Caldwell, A. & Hoffmann, A. A single NF-kappaB system for both canonical and non-canonical signaling. Cell Res. 21, 86-102 (2011).
18. Thompson, A. et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 75, 1895-1904 (2003). (Pubitemid 36438013)
19. Bengoechea-Alonso, M. T. & Ericsson, J. Tumor suppressor Fbxw7 regulates TGFbeta signaling by targeting TGIF1 for degradation. Oncogene 29, 5322-5328 (2010).
20. Mao, J. H. et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321, 1499-1502 (2008).
21. Liu, N. et al. The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J. Biol. Chem. 285, 18858-18867 (2010).
22. Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S. & Brunak, S. Prediction of post-Translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633-1649 (2004). (Pubitemid 38738322)
23. Xiao, G., Harhaj, E. W. & Sun, S. C. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol. Cell 7, 401-409 (2001). (Pubitemid 32206507)
24. Derudder, E. et al. RelB/p50 dimers are differentially regulated by tumor necrosis factor-Alpha and lymphotoxin-beta receptor activation: critical roles for p100. J. Biol. Chem. 278, 23278-23284 (2003). (Pubitemid 36830141)
25. Xiao, G. et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 20, 6805-6815 (2001). (Pubitemid 33134210)
26. Basak, S. et al. A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128, 369-381 (2007). (Pubitemid 46123518)
27. Bernal-Mizrachi, L., Lovly, C. M. & Ratner, L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl Acad. Sci. USA 103, 9220-9225 (2006). (Pubitemid 43902559)
28. Busino, L. et al. Fbxw7alpha-And GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat. Cell Biol. 14, 375-385 (2012).
29. Wang, Y. et al. NF-kappaB2 p100 is a pro-Apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 4, 888-893 (2002). (Pubitemid 35331364)
30. Perkins, N. D. The diverse and complex roles of NF-kappaB subunits in cancer. Nat. Rev. Cancer 12, 121-132 (2012).
31. Nadiminty, N. et al. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc. Natl Acad. Sci. USA 103, 7264-7269 (2006). (Pubitemid 43727821)
32. Liang, C., Zhang, M. & Sun, S. C. beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870. Cell Signal 18, 1309-1317 (2006). (Pubitemid 43674034)
33. Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131-144 (2007). (Pubitemid 47208626)
34. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115-130 (2007). (Pubitemid 47199123)
35. Xiao, G., Rabson, A. B., Young, W., Qing, G. & Qu, Z. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev. 17, 281-293 (2006). (Pubitemid 44038617)
36. Xiao, G. & Fu, J. NF-kappaB and cancer: a paradigm of Yin-Yang. Am. J. Cancer Res. 1, 192-221 (2011).
37. Staudt, L. M. Oncogenic activation of NF-kappaB. Cold Spring Harb. Perspect. Biol. 2, a000109 (2010).
38. van Drogen, F. et al. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23, 37-48 (2006).
39. Rocha, S., Martin, A. M., Meek, D. W. & Perkins, N. D. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol. Cell. Biol. 23, 4713-4727 (2003). (Pubitemid 36740458)
40. Lerner, M. et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell cycle 10, 2172-2183 (2011).
41. van Uden, P. et al. Evolutionary conserved regulation of HIF-1ß by NF-kappaB. PLoS Genet. 7, e1001285 (2011).
42. Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125-134 (2009).
43. Eriksson, H. et al. Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of small cell lung cancer resistance mechanisms. Proteomics 8, 3008-3018 (2008).
44. Kall, L., Canterbury, J. D., Weston, J., Noble, W. S. & MacCoss, M. J. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat. Methods 4, 923-925 (2007). (Pubitemid 350042380)
45. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res. 39, D214-D219 (2011).
46. Forshed, J. et al. Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ). Mol. Cell Proteomics 10, M111 010264 (2011).
47. Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116-5121 (2001). (Pubitemid 32397092)